Sandalan, Proceso D.
HRN: 03-57-23 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/30/2023
MUPIROCIN 2%, 15G (TUBE)
09/30/2023
10/07/2023
TOPICAL
2%
BID
S/P Incision Biopsy Site
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes